Immune Function and the Progression to T1D

Part of paid clinical trials in Gainesville, Florida.

Sponsor
University of Florida
Study ID
NCT05899439
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
0 Years - 100 Years
Healthy Volunteers
Accepted

Interventions

  • blood draw — OTHER
    a peripheral blood draw

Study Details

To elucidate the mechanisms by which type 1 diabetes-associated genes; IFIH1, TYK2, IKZF4, as well as total genetic risk, impart functional immunoregulatory abnormalities that result in expansion of self-reactive adaptive immune cells, defective regulatory/effector mechanisms in T cells, inflammatory antigen presenting cells, and abnormal immune function in T cells and B cells.

Key Dates

Start date
Jan 1, 2005
Status verified
Apr 2026
Primary completion
Jan 1, 2085
Completion
Jan 1, 2085

Study Design

Enrollment
2,800 participants (estimated)

Arms

  • Arm: Subjects with diabetes age 0 to 100 years
    People who have not been diagnosed with type 1 diabetes
  • Arm: Subjects with type 1 diabetes age 0 to 100 years
    People who have been diagnosed with type 1 diabetes

Primary Outcome Measure

the number of participants who become at risk for development of type 1 diabetes [ Time Frame: through study completion, up to 25 years ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Kieran McGrailGainesvilleFlorida32610
Kieran McGrail
352-273-9299
Todd Brusko, PhD (PRINCIPAL_INVESTIGATOR)
The Ohio State UniversityColumbusOhio43210
Billur Akkaya, MD DPhil
614-688-1187
Baylor College of Medicine, Center for Research Advancement - Texas Children's HospitalHoustonTexas77030
Maria Redondo, MD, PhD, MPH
832-822-1019
Franca Erhiawarie
832-824-3372

Find similar trials in Gainesville, FL

By condition
By specialty

Related Studies